Title: Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Authors: Wedzicha, Jadwiga A ×
Banerji, Donald
Chapman, Kenneth R
Vestbo, Jørgen
Roche, Nicolas
Ayers, R Timothy
Thach, Chau
Fogel, Robert
Patalano, Francesco
Vogelmeier, Claus F #
Contributors: Janssens, Wim
Issue Date: Jun-2016
Series Title: New England Journal of Medicine vol:374 issue:23
Article number: 10.1056/NEJMoa1516385
Abstract: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Pneumology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
nejmoa1516385.pdfOA article Published 398KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science